Increased concentrations of prostaglandin D2 during post-fracture bone remodeling

Journal of Rheumatology

Volumn 37, Issue 3, 2010, Pages 644-649

  Gallant, Maxime A ^a   Chamoux, Estelle ^a   Bisson, Martine ^a   Wolsen, Catarina ^a   Parent, Jean Luc ^a   Roux, Sophie ^a   De Brum Fernandes, Artur J ^a  

^a Centre Hospitalier Universitaire de Sherbrooke   (Canada)

Author keywords

Bone; Bone Remodeling; Fracture Repair; Prostaglandin Synthase

Indexed keywords

11 EPIPROSTAGLANDIN F2 ALPHA; ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; PROSTAGLANDIN D SYNTHASE; PROSTAGLANDIN D2; PROSTAGLANDIN E2;

ADULT; ARTICLE; BLOOD SAMPLING; BONE LEVEL; BONE REMODELING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRACTURE HEALING; HUMAN; IN VIVO STUDY; MALE; METABOLITE; OSSIFICATION; PRIORITY JOURNAL; URINALYSIS;

EID: 77949663899     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090622     Document Type: Article

References (41)

1. Szczesny G. Molecular aspects of bone healing and remodeling. Pol J Pathol 2002;53:145-53.
2. Bahar H, Benayahu D, Yaffe A, Binderman I. Molecular signaling in bone regeneration. Crit Rev Eukaryot Gene Expr 2007;17:87-101.
3. Dimitriou R, Tsiridis E, Giannoudis PV. Current concepts of molecular aspects of bone healing. Injury 2005;36:1392-404.
4. Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN, O'Keefe RJ. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 2002;109:1405-15.
5. Gerstenfeld LC, Thiede M, Seibert K, Mielke C, Phippard D, Svagr B et al. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. J Orthop Res 2003;21:670-5.
6. Simon AM, Manigrasso MB, O'Connor JP. Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 2002;17:963-76.
7. Vuolteenaho K, Moilanen T, Moilanen E. Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process. Basic Clin Pharmacol Toxicol 2008;102:10-4.
8. Bhattacharyya T, Levin R, Vrahas MS, Solomon DH. Nonsteroidal antiinflammatory drugs and nonunion of humeral shaft fractures. Arthritis Rheum 2005;53:364-7.
9. Giannoudis PV, MacDonald DA, Matthews SJ, Smith RM, Furlong AJ, De Boer P. Nonunion of the femoral diaphysis. The influence of reaming and non-steroidal anti-inflammatory drugs. J Bone Joint Surg Br 2000;82:655-8.
10. Raisz LG. Prostaglandins and bone: physiology and pathophysiology. Osteoarthritis Cartilage 1999;7:419-21.
11. Kostenis E, Ulven T. Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol Med 2006;12:148-58.
12. Hayaishi O. Molecular genetic studies on sleep-wake regulation, with special emphasis on the prostaglandin D(2) system. J Appl Physiol 2002;92:863-8.
13. Gallant MA, Samadfam R, Hackett JA, Antoniou J, Parent JL, de Brum-Fernandes AJ. Production of prostaglandin D(2) by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors. J Bone Miner Res 2005;20:672-81.
14. Koshihara Y, Amano T, Takamori R. Prostaglandin D2 stimulates calcification by human osteoblastic cells. Adv Prostaglandin Thromboxane Leukot Res 1991;21B:847-50.
15. Tasaki Y, Takamori R, Koshihara Y. Prostaglandin D2 metabolite stimulates collagen synthesis by human osteoblasts during calcification. Prostaglandins 1991;41:303-13.
16. Durand M, Gallant MA, de Brum-Fernandes AJ. Prostaglandin D2 receptors control osteoclastogenesis and the activity of human osteoclasts. J Bone Miner Res 2008;23:1097-105.
17. Urade Y, Eguchi N. Lipocalin-type and hematopoietic prostaglandin D synthases as a novel example of functional convergence. Prostaglandins Other Lipid Mediat 2002;68-69:375-82.
18. Jaggi GP, Flammer J, Huber AR, Killer HE. Lipocalin-like prostaglandin D synthase in subretinal fluid of detached retinas in humans. Retina 2008;28:858-63.
19. Inoue T, Eguchi Y, Matsumoto T, Kijima Y, Kato Y, Ozaki Y, et al. Lipocalin-type prostaglandin D synthase is a powerful biomarker for severity of stable coronary artery disease. Atherosclerosis 2008;201:385-91.
20. Barcelo A, de la Pena M, Barbe F, Pierola J, Bosch M, Agusti AG. Prostaglandin D synthase (beta trace) levels in sleep apnea patients with and without sleepiness. Sleep Med 2007;8:509-11.
21. Qu WM, Huang ZL, Xu XH, Aritake K, Eguchi N, Nambu F, et al. Lipocalin-type prostaglandin D synthase produces prostaglandin D2 involved in regulation of physiological sleep. Proc Natl Acad Sci USA 2006;103:17949-54.
22. Jordan W, Tumani H, Cohrs S, Eggert S, Rodenbeck A, Brunner E, et al. Prostaglandin D synthase (beta-trace) in healthy human sleep. Sleep 2004;27:867-74.
23. Yoshikawa R, Wada J, Seiki K, Matsuoka T, Miyamoto S, Takahashi K, et al. Urinary PGDS levels are associated with vascular injury in type 2 diabetes patients. Diabetes Res Clin Pract 2007;76:358-67.
24. Hirawa N, Uehara Y, Ikeda T, Gomi T, Hamano K, Totsuka Y, et al. Urinary prostaglandin D synthase (beta-trace) excretion increases in the early stage of diabetes mellitus. Nephron 2001;87:321-7.
25. Schett G. Review: Immune cells and mediators of inflammatory arthritis. Autoimmunity 2008;41:224-9.
26. Huang W, Schwarz EM. Mechanisms of bone resorption and new bone formation in spondyloarthropathies. Curr Rheumatol Rep 2002;4:513-7.
27. Goldring SR. The role of bone in osteoarthritis pathogenesis. Rheum Dis Clin North Am 2008;34:561-71.
28. Cochran DL. Inflammation and bone loss in periodontal disease. J Periodontol 2008;79:1569-76.
29. Mundy GR. Osteoporosis and inflammation. Nutr Rev 2007;65:S147-51.
30. Hackett JA, Allard-Chamard H, Sarrazin P, de Fatima Lucena M, Gallant MA, Fortier I, et al. Prostaglandin production by human osteoclasts in culture. J Rheumatol 2006;33:1320-8.
31. Dekel S, Lenthall G, Francis MJ. Release of prostaglandins from bone and muscle after tibial fracture. An experimental study in rabbits. J Bone Joint Surg Br 1981;63-B:185-9.
32. Paralkar VM, Borovecki F, Ke HZ, Cameron KO, Lefker B, Grasser WA, et al. An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Natl Acad Sci USA 2003;100:6736-40.
33. Li M, Healy DR, Li Y, Simmons HA, Crawford DT, Ke HZ, et al. Osteopenia and impaired fracture healing in aged EP4 receptor knockout mice. Bone 2005;37:46-54.
34. Bochenek G, Nizankowska E, Gielicz A, Swierczynska M, Szczeklik A. Plasma 9α,11ß-PGF2, a PGD2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma. Thorax 2004;59:459-64.
35. Bochenek G, Nagraba K, Nizankowska E, Szczeklik A. A controlled study of 9α,11ß-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol 2003;111:743-9.
36. Nagakura T, Obata T, Shichijo K, Matsuda S, Sigimoto H, Yamashita K, et al. GC/MS analysis of urinary excretion of 9α, 11ß-PGF2 in acute and exercise-induced asthma in children. Clin Exp Allergy 1998;28:181-6.
37. Hirawa N, Uehara Y, Yamakado M, Toya Y, Gomi T, Ikeda T, et al. Lipocalin-type prostaglandin d synthase in essential hypertension. Hypertension 2002;39:449-54.
38. Almishri W, Cossette C, Rokach J, Martin JG, Hamid Q, Powell WS. Effects of prostaglandin D2, 15-deoxy-Delta 12,14-prostaglandin J2, and selective DP1 and DP2 receptor agonists on pulmonary infiltration of eosinophils in Brown Norway rats. J Pharmacol Exp Ther 2005;313:64-9.
39. Ulven T, Kostenis E. Targeting the prostaglandin D2 receptors DP and CRTH2 for treatment of inflammation. Curr Top Med Chem 2006;6:1427-44.
40. Probst A, Spiegel HU. Cellular mechanisms of bone repair. J Invest Surg 1997;10:77-86.
41. Frost HM. The biology of fracture healing. An overview for clinicians. Part I. Clin Orthop Relat Res 1989;248:283-93.